Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 4, 2007 Billy Fisher	Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note.
The Motley Fool March 31, 2010 Brian Orelli	A Double-Digit Jump? For That? Isis' drug discovery license doesn't look too exciting to me.
The Motley Fool February 12, 2009 Brian Orelli	Cruising, but Ready to Take Off Genzyme's in wait-and-see mode.
The Motley Fool May 25, 2005 Brian Gorman	Another Deal for Isis Investors shouldn't get their hopes up over the drugmaker's latest collaboration.
The Motley Fool May 17, 2011 Brian Orelli	$3 Million Here, $1.5 Billion There Isis makes progress in its pact with GlaxoSmithKline.
The Motley Fool September 14, 2007 Brian Orelli	J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note.
The Motley Fool January 9, 2008 Brian Orelli	Genzyme Buys Into Antisense RNA -- Big Time Genzyme buys a piece of Isis' mipomersen at a wowser of a price.
The Motley Fool February 4, 2008 Brian Lawler	Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note.
The Motley Fool December 14, 2010 Travis Hoium	Lexicon Pharmaceuticals Shares Plunged: What You Need to Know Lexicon Pharmaceuticals shares fell as much as 14% in intraday trading on disappointing results of its rheumatoid arthritis drug test.
The Motley Fool May 15, 2007 Mike Havrilla	Eyeing ISIS A robust pipeline and a promising cholesterol drug could benefit this pharmaceutical firm. Investors, take note.
The Motley Fool July 28, 2011 Travis Hoium	Corn Products International Shares Plunged: What You Need to Know Shares of Corn Products International fell as much as 13% in intraday trading today after the company released earnings.
The Motley Fool June 23, 2010 Brian Orelli	A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner.
The Motley Fool October 12, 2006 Brian Lawler	Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading.
The Motley Fool October 13, 2010 Travis Hoium	Keryx Biopharmaceuticals Shares Popped: What You Need to Know Keryx Biopharmaceuticals Inc. shares jumped 10% in intraday trading today, on over three times the average volume for the last three months.
The Motley Fool December 4, 2008 Brian Orelli	Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen.
The Motley Fool May 20, 2009 Brian Orelli	Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game.
The Motley Fool January 6, 2004 David Nierengarten	Isis' 2G Drug Shines Will Isis start making cents from anti-sense drugs?
The Motley Fool January 11, 2011 Brian Orelli	A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme.
The Motley Fool December 18, 2008 Brian Orelli	A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
The Motley Fool November 22, 2011 Luke Timmerman	Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring Pfizer is making a new bet on a new drug to fight excessive scarring.
The Motley Fool October 25, 2007 Brian Lawler	Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation?
The Motley Fool May 2, 2011 Cindy Johnson	Central Fund of Canada Shares Plunged: What You Need to Know Central Fund of Canada dropped 13% in intraday trading today on heavy volume after futures prices for silver plummeted.
The Motley Fool November 16, 2011 Matt Koppenheffer	Abercrombie & Fitch Shares Got Crushed: What You Need to Know Shares of teen fashionista Abercrombie & Fitch were looking out of style to investors today as they fell as much as 16% in intraday trading after reporting third-quarter results.
The Motley Fool April 28, 2008 Brian Orelli	FDA Moves Isis' Finish Line The FDA tells drugmaker Isis it must complete cancer tests before submitting its marketing application.
The Motley Fool May 20, 2011 Travis Hoium	Camelot Information Systems Shares Popped: What You Need to Know Shares of Camelot Information Systems jumped as much as 16% briefly in a spike early in intraday trading Friday after quarterly revenue beat expectations.
The Motley Fool September 28, 2011 Brian D. Pacampara	Home Inns & Hotels Management Shares Plunged: What You Need to Know Shares of Chinese hotel operator Home Inns & Hotels Management sank 15% in intraday trading today on above-average volume.
The Motley Fool November 18, 2009 Brian Orelli	Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data.
The Motley Fool April 9, 2008 Brian Orelli	Isis Ignited by Bristol-Myers Bristol-Myers Squibb selects an Isis-developed compound, triggering a milestone payment.
The Motley Fool October 29, 2004 Brian Gorman	Elan Bides Its Time Is the Irish pharmaceutical stronger from its near-death experience?
The Motley Fool April 24, 2008 Brian Lawler	FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results.
The Motley Fool October 28, 2010 Matt Koppenheffer	United Community Banks Shares Plunged: What You Need to Know Shares of Georgia banking group United Community Banks slid more than 13% in intraday trading as investors reacted to the bank's third-quarter earnings report. Is this meaningful? Or just another movement?
BusinessWeek November 27, 2006 Gene G. Marcial	ISIS Takes Heart From A Promising Drug ISIS Pharmaceuticals is a name to watch in the lucrative arena of cholesterol reduction.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool July 22, 2011 Cindy Johnson	Advanced Micro Devices Shares Popped: What You Need to Know Advanced Micro Devices popped 19% in intraday trading today after delivering a better-than-expected quarter and outlook.
InternetNews May 17, 2007 Paul Shread	Technical Analysis: S&P Still Can't Get the Job Done Market rallies have been stopped by the same trendline for the last six months.
The Motley Fool October 20, 2010 Tim Beyers	Complete Production Services Shares Popped: What You Need to Know Shares of Complete Production Services soared more than 10% on intraday trading after the oil services company reported revenue and earnings that soundly beat Wall Street projections.
The Motley Fool April 21, 2009 Brian Orelli	Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply.
InternetNews June 19, 2007 Paul Shread	Technical Analysis: Let's Make a Deal The market is stalling for lack of blockbuster merger news.
The Motley Fool October 11, 2010 Travis Hoium	AOB Shares Popped: What You Need to Know Shares of American Oriental Bioengineering rose 10% in intraday trading on unusually high volumes.
The Motley Fool June 16, 2009 Brian Orelli	Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs.
The Motley Fool December 17, 2008 Brian Orelli	A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off.
The Motley Fool August 4, 2011 Travis Hoium	Cooper Tire & Rubber Shares Plunged: What You Need to Know Shares of Cooper Tire & Rubber locked up the brakes Thursday and fell 26% in intraday trading.
The Motley Fool August 1, 2008 Brian Lawler	Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug.
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
The Motley Fool February 17, 2004 David Nierengarten	Antisense Making Sense? An update on Genasense, its future, and how the antisense marketplace is shaping up. The FDA has agreed to review the new drug applications.
The Motley Fool October 13, 2010 Matt Koppenheffer	Phoenix Cos. Shares Popped: What You Need to Know Shares of insurer Phoenix Cos. surged more than 10% in intraday trading on no apparent news.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool June 29, 2009 Brian Orelli	Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder.